Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial [1] [2] [3] [4] Niamh Phelan, Annalouise O'Connor, Tommy Kyaw Tun, Neuman Correia, Gerard Boran, Helen M Roche, and James Gibney ABSTRACT Background: Polycystic ovary syndrome (PCOS) is characterized by an adverse metabolic profile. Although dietary changes are advocated, optimal nutritional management remains uncertain. Polyunsaturated fatty acids (PUFAs), particularly long-chain (LC) n23 (omega-3) PUFAs, improve metabolic health, but their therapeutic potential in PCOS is unknown. Objectives: We aimed to determine the associations between plasma PUFAs and metabolic and hormonal aspects of PCOS to investigate the efficacy of LC n23 PUFA supplementation and to support the findings with mechanistic cellular studies. Design: We selected a cross-sectional PCOS cohort (n = 104) and conducted a principal component analysis on plasma fatty acid profiles. Effects of LC n23 PUFA supplementation on fasting and postprandial metabolic and hormonal markers were determined in PCOS subjects (n = 22) by a randomized, crossover, placebocontrolled intervention. Direct effects of n26 (omega-6) compared with n23 PUFAs on steroidogenesis were investigated in primary bovine theca cells. Results: Cross-sectional data showed that a greater plasma n26 PUFA concentration and n26:n23 PUFA ratio were associated with higher circulating androgens and that plasma LC n23 PUFA status was associated with a less atherogenic lipid profile. LC n23 PUFA supplementation reduced plasma bioavailable testosterone concentrations (P , 0.05), with the greatest reductions in subjects who exhibited greater reductions in plasma n26:n23 PUFA ratios. The treatment of bovine theca cells with n26 rather than with n23 PUFAs up-regulated androstenedione secretion (P , 0.05). Conclusions: Cross-sectional data suggest that PUFAs modulated hormonal and lipid profiles and that supplementation with LC n23 PUFAs improves androgenic profiles in PCOS. In bovine theca cells, arachidonic acid modulated androstenedione secretion, which suggests an indirect effect of n23 PUFAs through the displacement of or increased competition with n26 PUFAs. This trial was registered at clinicaltrials.gov as NCT01189669.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism and anovulation and affects 5-10% of women of reproductive age (1) . Insulin resistance is a common finding, and has been linked with the pathogenesis of PCOS. Women with PCOS are more likely to develop type 2 diabetes (2), and there is some evidence to support an increase in cardiovascular disease (CVD) risk (3) (4) (5) .
Dietary and lifestyle interventions, with an emphasis on weight management, are usually among the first-line treatments for women with PCOS. However, overweight and obesity are not global findings (6) , and little is known about the optimal diet for this group beyond energy restriction. Dietary fats are now recognized as biological regulators that influence various aspects of metabolic health (7) . Polyunsaturated fatty acids (PUFAs), particularly those of the n23 family, are perhaps the most potent fatty acid regulators of metabolic function and are implicated in a diverse range of processes in vivo (8) . The beneficial effect of long-chain (LC) n23 PUFAs on CVD risk reduction has been particularly well characterized (9) and is mediated in part by the hypotriglyceridaemic effect of LC n23 PUFAs, which has been shown under fasting (10, 11) and postprandial conditions (12) . The generation of less-potent eicosanoids involved in blood pressure, inflammation, and platelet aggregation in the setting of increased LC n23 PUFAs may also be involved in reduced CVD risk (13) . In addition, evidence exists for an antiandrogenic effect of n23 PUFAs within the context of prostate cancer, although the mechanisms mediating this effect are unclear (14) (15) (16) .
Two studies have examined the effects of n23 PUFAs in PCOS. The first study supplemented the diet of women with PCOS with a-linolenic acid (17) ; however, plant sources of n23 PUFAs compared with longer-chain fatty acids of marine origin such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) shown in fish oil are less-potent biological regulators (8) , and this study did not show a therapeutic effect. A second study that supplemented with the LC n23 PUFAs EPA and DHA showed some beneficial effects on triacylglycerol and liver-fat contents, but oral contraceptive pill use by study participants precluded the study of androgens in this cohort (18) .
To further explore the effect of PUFAs in PCOS, we used 3 different study methodologies. First, we explored the associations between hormonal and metabolic environments of PCOS and plasma fatty acid composition, which is a biomarker of habitual dietary fat intake (19) , in a cross-sectional cohort of women with PCOS. Second, we evaluated the metabolic and hormonal effects of LC n23 PUFA supplementation in women with PCOS. Because postprandial hyperlipidemia has been shown in PCOS (20, 21) and is a significant risk factor for CVD (22, 23) , potential therapeutic effects of LC n23 PUFAs in postprandial metabolism and hormonal status were of particular interest. Finally, we investigated the direct effect of n26 compared with n23 PUFAs on steroidogenesis in primary bovine theca cells.
SUBJECTS AND METHODS

Assessment of relations between plasma fatty acid composition and lipid and androgen profiles in a cross-sectional cohort of women with PCOS
This observational study was retrospectively registered at clinicaltrials.gov as NCT01195168. All study participants gave written informed consent before participating in the study, which was approved by the Research Ethics Committee of the Adelaide and Meath Hospital and St James' Hospital (Dublin, Ireland). A total of 104 premenopausal white women with PCOS were recruited from the Endocrinology and combined Endocrinology and Gynecology clinics in the Adelaide and Meath Hospital. PCOS was defined according to the National Institutes of Health criteria (1991) as chronic oligomenorrhea (,9 menstrual cycles/y) and clinical or biochemical evidence of hyperandrogenism in the absence of other disorders that caused the same phenotype. Clinical criteria included hirsutism with a Ferriman-Galwey score .9, acne, or male-pattern alopecia, and biochemical criteria included total testosterone, androstenedione, or dehydroepiandrosterone sulfate (DHEAS) concentrations greater than the laboratory reference range. Exclusion criteria were as follows: ,18 or .40 y old, pregnant or lactating, body mass index (BMI; in kg/m 2 ) ,18 or .50, recent illness, or taking any medications that were likely to influence the results, including hormonal contraception, antihypertensive medications, and lipid-lowering, antiplatelet, or antiinflammatory agents. All subjects attended the Diabetes Day Centre in the Adelaide and Meath Hospital after a 12-h fast, having avoided excessive exercise and alcohol for the previous 24 h. A 75-g oral-glucosetolerance test was performed in each volunteer. Glucose and insulin concentrations were measured fasting and 2-h post oral glucose load. Fasting blood samples were taken for analysis of plasma hormones and plasma fatty acids. Height (measured with a Harpenden stadiometer) and weight were measured. Waist circumference (WC) and hip circumference (HC) were measured with a nondistensible flexible tape measure at the waist and hip. BMI was calculated as weight (in kg) divided by height (in m   2 ). The waist-to-hip ratio (WHR) as a measure of central adiposity was calculated by the WC (cm) divided by the HC (cm).
A principal component analysis (PCA) of 11 plasma fatty acids was conducted within a previously described cohort of PCOS women (n = 104) (24) . A closely linked relation exists between fatty acids, with a change in the proportion of one influencing the proportions of several others (25) . Therefore, the aim of this analysis was to define potential plasma fatty acid composition signatures and to relate these to the metabolic and endocrine profiles of women with PCOS. Before performing PCA, the suitability of the data for factor analysis was assessed. An inspection of the correlation matrix revealed the presence of many coefficients 0.3. The Kaiser-Meyer-Olkin value was 0.768, which exceeded the minimum recommended value of 0.6. Bartlett's test of sphericity reached statistical significance (P , 0.001), which further supported the factorability of the matrix. PCA revealed 3 components with eigenvalues .1.0; however, an inspection of the factor matrix generated and the loading values of the various fatty acids to each factor supported the use of a 2-factor solution only. This solution explained 64.7% of the variance of plasma fatty acids within the group, with factors 1 and 2 contributing 47.9% and 16.8%, respectively. To aid the interpretation of these 2 components, an oblimin rotation was performed, which revealed a simple structure with a number of components that strongly loaded onto each factor. Details of the factors generated are presented in Table 1 .
The effect of LC n23 PUFA supplementation on hormonal and metabolic variables in women with PCOS
Study design
This study was approved by the Research Ethics Committee of the Adelaide and Meath Hospital and St James' Hospital. This trial was retrospectively registered at clinicaltrials.gov as NCT01189669. This study was a randomized, double-blind, placebo-controlled, crossover trial of LC n23 PUFA supplementation compared with a placebo in women with PCOS and took place from September 2007 to July 2008 when all subjects had completed all study arms. After recruitment and eligibility assessment by the study investigators, subjects were randomly assigned to receive either a LC n23 PUFA supplement or olive- oil placebo for 6 wk (see supplemental data for composition under "Supplemental data" in the online issue). This procedure was followed by a 6-wk washout to minimize the carry-over effect from the previous treatment, after which subjects crossed over to receive the alternative treatment. At baseline and after each treatment period, subjects attended the diabetes day center in the Adelaide and Meath Hospital for metabolic studies.
Experimental subjects
Thirty-four premenopausal women with PCOS were recruited for the study from endocrinology outpatient clinics (Adelaide and Meath Hospital). PCOS was defined according to the National Institutes of Health criteria as chronic oligomenorrhea (,9 menstrual cycles/y) and clinical or biochemical evidence of hyperandrogenism in the absence of other disorders that cause the same phenotype. Clinical criteria included hirsutism with a Ferriman-Galwey score .9, acne, or male-pattern alopecia; biochemical criteria included total-testosterone, androstenedione, or DHEAS concentrations greater than the laboratory reference range. Subjects were excluded if they were ,18 or .40 y old, nonwhite, pregnant, lactating, or trying to conceive, had a BMI ,18 or .50, had a recent illness or any chronic illness likely to influence results, were taking any medications likely to influence the results including hormonal contraception, antihypertensives, lipid-lowering medications, antiplatelet agents, antiinflammatory agents, were taking nutritional supplements, or consumed .2 portions of oily fish/wk. Subjects who were taking a stable dose of metformin for .6 wk were included. Any subject who had previously taken the oral contraceptive pill ceased its use 3 mo before the commencement of the study period. All study subjects gave their written signed consent to participate in the study. In total, 34 women were recruited for the study. After screening, 25 women were deemed eligible and enrolled, of which 22 women completed all study days ( Figure 1 ). These 22 subjects were taken forward into the final analysis.
Details of LC n23 PUFA supplements and placebo
The LC n23 PUFA supplement was given as 4 · 1-g capsules/d. This was a commercial product (Seven Seas, Dublin, Ireland), and provided 2.4 g LC n23 PUFAs that contained 1.9 g EPA and DHA/d in a ratio of EPA:DHA of 1.49:1. The placebo was given as 4 · 1-g olive oil capsules (Millas Inc, Portland, OR). This was deemed a suitable placebo because low intakes of olive oil are not considered to have a biochemical effect (26) . The fatty acid composition of both supplements was confirmed by assessors unaffiliated with the study by using gas chromatography (Cal Ltd, Dublin, Ireland).
The compositions of the LC n23 PUFA supplement and oliveoil placebo are presented in Table 2 . Placebo LC n23 PUFA capsules were similar in size and color, and all supplements were stored in opaque containers and ascribed the labels diet A or diet B by an individual independent of the investigation. This individual held the supplement key until all participants had completed the study, at which point the study was unblinded. Participants, intervention providers, outcome analyzers, and statisticians were blinded during the course of this study. To prevent lipid oxidation, each capsule contained 0.7 mg vitamin E. Peroxide and p-anisidine concentrations as measures of primary and secondary lipid oxidation were assessed in oil supplements at baseline and upon completion of the study. This analysis conducted by Cal Ltd (Dublin, Ireland) did not indicate the presence of lipid peroxidation (data not shown).
Subject compliance was assessed by a capsule count and plasma fatty acid compositional assessment before and after each supplementation period. No side effects were reported in either arm of the intervention.
Both interventions were separated by a 6-wk washout period. This washout period was deemed to be sufficient on the basis of a report that showed that, after 4 wk of 4 g fish-oil supplementation, triacylglycerol concentrations returned to baseline after 4 wk of supplement cessation (11) .
Assessment of body composition, nutritional status, and lifestyle variables
All subjects underwent estimations of body composition at baseline and after each treatment period by using auxiologic methods and bioimpedence analysis. Height (measured with a Harpenden stadiometer) and weight were measured in a hospital gown. WC and HC were measured with a nondistensible flexible tape measure at the waist and hip, and WHR was calculated. The percentage of body fat was estimated with the Bodystat 1500 system (Bodystat Ltd, Onchan, United Kingdom). Participants were requested to maintain habitual diet and lifestyle patterns for the duration of the study. A health and lifestyle questionnaire was used to assess smoking-and alcohol-consumption behaviors as well as menstrual cyclicity. A validated physical activity questionnaire (27) and a 3-d food diary were completed for each study day. The 3-d food diaries were quantified by a qualified dietitian, analyzed for macronutrient composition with the use of NET-WISP software (version 2.0; Tinuviel software, Warrington, United Kingdom), and exported to SPSS software (version 14; Chicago, IL) for statistical analyses.
Metabolic studies
Subjects attended the Diabetes Day Centre at the Adelaide and Meath Hospital Incorporating the National Children's Hospital and were studied after a 12-h overnight fast having avoided excessive exercise and alcohol for the preceding 24 h. After fasting blood samples were obtained, participants consumed a test meal over 20 min. A mixed meal was chosen to characterize the postprandial responses of lipid, insulin, and glucose concentrations and consisted of one 80-g muffin, 3 slices (75 g) of white bread, 20 g full-fat butter, 250 mL flavored milk, and 2 slices (30 g) of cheddar cheese. This meal provided 1174 kcal, 34.7 g protein, 116.5 g carbohydrate, and 64 g of fat (32.8 g saturated fatty acid, 22.6 g monounsaturated fatty acid, and 7.7 g PUFA). Blood samples were drawn at 15, 30, 60, 90, 120, 240, 360, and 480 min after completion of the test meal.
Laboratory methods
Fasting and postprandial assessments of metabolic markers were assessed as primary outcome measures. Fasting and postprandial plasma glucose, insulin, lipid, nonesterified fatty acids (NEFA), and apolipoprotein B48 concentrations were measured. Glucose, total cholesterol, triacylglycerol, and HDL cholesterol concentrations were measured by using an enzymatic colorimetric method (Cobas Roche Diagnostics Ltd, West Sussex, United Kingdom) in the Roche P Module (Roche, Stockholm, Sweden). Insulin was measured with an electrochemiluminesence immunoassay (Cobas Roche Diagnostics Ltd) on the Roche E Module (Roche). NEFA was measured by using an enzymatic colorimetric method with a commercially available kit (Wako Chemicals, Neuss, Germany). LDL cholesterol was calculated by using Friedwald's equation. Apolipoprotein B48 was measured by using an enzyme-linked immunosorbent assay with a commercially available kit (Gentaur, Kampenhout, Belgium). Fasting concentrations of glucose and insulin were used to calculate the homeostatic model assessment (HOMA) (28) . The postprandial glucose, insulin, and lipid incremental area under the curve were determined by using the trapezoidal rule (29) . Plasma fatty acids were extracted and methylated as previously described (30) and analyzed by gas chromatography on a Shimadzu GC 2010 chromatograph (Shimadzu, Tokyo, Japan) with a fused silica capillary column (Omegawax 250; inner diameter: 30 m · 0.25 mm; 0.25-lm film; Supelco, Bellefonte, PA).
A fasting hormonal profile was assessed as a key secondary outcome measure. Concentrations of fasting plasma hormone including sex-hormone binding globulin (SHBG) and DHEAS were In vitro assessment of androgen production from ovarian theca cells in response to PUFA Briefly, bovine ovaries were collected at a local abattoir immediately after slaughter and returned to the laboratory in 1 h. Theca cells were obtained from small follicles as previously described (31) . Cells were counted by using Trypan Blue and deemed to be .80% viable (data not shown). Cells were plated at a density of 1.5 · 10 6 cells/mL in a 96-well plate (Nunc, Roskilde, Denmark) and maintained at 37°C and 5% CO 2 in air in a humidified incubator. Androstenedione secretion was induced and maintained in response to physiologic concentrations of luteinizing hormone (LH). In addition, cells were treated with 50-lmol/L concentrations of either EPA, arachidonic acid (AA), or DHA (Sigma-Aldrich, Dorset, United Kingdom) prepared in sterile dimethyl sulfoxide. For all experiments, dimethyl sulfoxide concentrations were ,0.1% in the final culture medium. Theca cells were treated in triplicate, and treatments were compared with a vehicle control. Concentrations of androstenedione in the cell media were analyzed by using Coat-a-Count radioimmunoassays (Cruinn Diagnostics).
Statistical analyses
Data are presented as means 6 SDs. Skewed variables were logarithmically transformed before analysis and checked for Gaussian distribution before use in further analysis. Independent t tests were used to explore differences between groups in the cross-sectional analysis. Analysis of covariance was used to compare between-group differences, whereas confounding variables, including BMI, WHR, SHBG, and HOMA, were controlled for. To explore the effect of LC n23 PUFA supplementation, the change from baseline was calculated for each variable. Onefactor repeated-measures analysis of variance with the supplement order controlled for was conducted to determine the significance of changes in biomarkers after LC n23 PUFAs compared with after placebo treatment. To explore the effect of fatty acid treatments of bovine theca cells, analysis of variance was used. Correlations between variables were explored by using Pearson product-moment correlation coefficients. All statistical analyses were performed with SPSS for Windows (version 14; SPSS Inc).
RESULTS
Plasma n26 PUFA status was associated with hyperandrogenemia in a cross-sectional cohort of women with PCOS Clinical characteristics of this cohort of women with PCOS (n = 104) are presented in Table 3 . PCA analysis to determine the effect of plasma fatty acid composition on hormonal status in a cross-sectional cohort of women with PCOS (n = 104) generated 2 factors (Table 1) . Factor 1 was deemed a high plasma n26 PUFA factor with linoleic acid, c-linolenic acid (GLA), dihomoc-linolenic acid (DGLA), and AA all loading strongly. Factor 2 was considered a high plasma LC n23 PUFA factor with high loadings of EPA and DHA. Within the total cross-sectional PCOS cohort, a high plasma n26 PUFA status correlated significantly with testosterone (r = 0.333, P = 0.013) and DHEAS (r = 0.288, P = 0.033), whereas no similar relation was observed between n23 PUFA status and androgens. In support of this, we observed that the n26: n23 PUFA ratio was positively correlated with testosterone (r = 0.451, P = 0.049). When scores for the high plasma n26 PUFA factor were dichotomized above and below the median for plasma n26 PUFA status, independent t tests revealed that those women with high plasma n26 PUFA status had significantly higher circulating testosterone and DHEAS concentrations (Figure 2A) , despite no significant between-group differences in terms of BMI (P = 0.245), WHR (P = 0.796), SHBG (P = 0.366), or HOMA (P = 0.115). A less pronounced relation between plasma PUFAs and androgens was also observed in the control cohort (data not shown).
A greater plasma LC n23 PUFA status was associated with a healthier lipid profile in women with PCOS. When scores for the high plasma LC n23 PUFA factor were dichotomized above and below the median for plasma LC n23 PUFA status, it was revealed that those women with a greater plasma LC n23 PUFA status had significantly lower circulating metabolic lipid markers (triacylglycerol and triacylglycerol:HDL) ( Figure 2B ). Similar relations were also observed in the control cohort (data not shown).
Baseline characteristics of subjects in the dietary intervention study and change in diet and lifestyle variables over the course of the intervention study Independent t tests conducted between those subjects who received the LC n23 PUFA supplement first and those subjects who received the placebo supplement first revealed no significant between-group differences in baseline age, anthropometric measures, hormonal status, lipid profile, dietary intake data, or plasma fatty acid concentrations (see supplemental Table 1 under "Supplemental data" in the online issue).
No significant change in dietary macronutrients, smoking, alcohol intake, or physical activity levels were observed over the course of the study (see supplemental Table 2 under "Supplemental data" in the online issue). No change in micronutrient profiles were observed (data not shown).
LC n23 PUFA supplementation increased plasma concentrations of n23 PUFAs and had an antiandrogenic effect in PCOS
There was a significant increase in plasma EPA and DHA concentrations after LC n23 PUFA supplementation ( Table 4) . No significant differences were observed after placebo supplementation compared with baseline, which thus eliminated the possibility of carry over. The total plasma n26 PUFA concentration was not significantly altered by LC n23 PUFA supplementation, although concentrations of dihomo-c-linolenic acid were significantly lower after LC n23 PUFA supplementation than after placebo intake. These changes in n23 fatty acids contributed to a significantly lower plasma n26: n23 PUFA ratio after LC n23 PUFA supplementation than after placebo intake.
Bioavailable testosterone concentrations were significantly reduced after LC n23 PUFA supplementation than after placebo intake (P , 0.05), whereas there were nonsignificant reductions in total-testosterone, DHEAS, and androstenedione concentrations and no change in SHBG concentrations (Figure 3) . No significant changes in concentrations of other reproductive hormones (estrogen, LH, or follicle stimulating hormone) were observed (data not shown). Because of the results obtained from PCA within the independent cross-sectional cohort, we further explored these changes in plasma androgen concentrations by dichotomizing the intervention cohort above and below the median of change for bioavailable testosterone concentrations ( Table 5 ). This analysis showed that PCOS subjects with the greatest reduction in bioavailable testosterone concentrations (.0.50 nmol/L) showed significantly greater reductions in total testosterone, androstenedione, and FAI concentrations compared with subjects who showed little change in bioavailable testosterone concentrations (0.50 nmol/L). Subjects who showed a greater reduction in bioavailable-testosterone concentrations also showed a significantly greater reduction in the n26: n23 PUFA ratio.
LC n23 PUFA supplementation did not reduce plasma triacylglycerol in PCOS
Fasting and postprandial plasma triacylglycerol and apoB48 concentrations did not change in response to LC n23 PUFA supplementation (see supplemental Table 3 and Figure 1 , A and B, High plasma n26 polyunsaturated fatty acid (PUFA) concentrations were associated with hyperandrogenemia, whereas low plasma long-chain n23 PUFA concentrations were associated with a more deleterious lipid profile in women with polycystic ovary syndrome (n = 104). Mean (6SD) concentrations of testosterone (A) and dehydroepiandrosterone sulfate (DHEAS) (B) above and below the median of plasma n26 status, and mean (6SD) concentrations of triacylglycerol (C) and triacylglycerol:HDL (D) above and below the median of plasma n23 status. *P , 0.05 (independent t tests between dichotomized groups).
under "Supplemental data" in the online issue). LC n23 PUFA plasma NEFA concentrations were significantly greater in the late postprandial phase after n23 PUFA supplementation (see supplemental Figure 1C under "Supplemental data" in the online issue). Fasting and postprandial total cholesterol, HDL cholesterol, and LDL cholesterol concentrations did not change (data not shown). There was also no change in fasting and postprandial glucose and insulin concentrations (see supplemental Table 3 and Figure 2 , A and B, under "Supplemental data" in the online issue). When the cohort was dichotomized above and below the median of change in circulating plasma triacylglycerol concentrations, t tests conducted between subjects above the median for change in . Mean (6SD) changes in plasma androgens at baseline and after long-chain n23 polyunsaturated fatty acid (LC n23 PUFA) supplementation compared with placebo supplementation for 6 wk in women (n = 22) with polycystic ovary syndrome. Bioavailable testosterone (A), dehydroepiandrosterone sulfate (DHEAS; B), sex hormone binding globulin (SHBG; C), and total testosterone (D) concentrations at baseline and after 6-wk of LC n23 PUFA or placebo (olive oil) supplementation. *P , 0.05 (repeated-measures ANOVA by using the change from baseline data and with supplement order controlled for).
triacylglycerol concentrations (change .0.11 mmol/L) had significantly higher plasma alanine aminotransferase (ALT) concentrations than did subjects with reduced triacylglycerol concentrations less than the median (,0.11 mmol/L) (ALT concentrations of 31.00 6 14.42 compared with 25.45 6 7.38 IU/L, respectively; P = 0.026).
Effects of PUFAs on steroidogenesis in primary bovine theca cells: AA but not EPA or DHA up-regulated steroidogenesis in bovine theca cells Given the positive effect of LC n23 PUFA supplementation on circulating androgens, we determined the direct effects of treatment with the n26 PUFA AA and LC n23 PUFAs EPA and DHA on steroidogenesis in bovine theca cells to explore whether this reflected a direct effect of EPA and DHA or competitive displacement of n26 PUFAs such as AA. As shown in Figure 4 , treatment of primary bovine theca cells with AA resulted in an increase in LH-induced androstenedione secretion. In contrast, treating bovine theca cells with LC n23 PUFAs (EPA or DHA) had no effect on androstenedione secretion (Figure 4) , which suggested that the effect observed in the human intervention study might have represented an indirect effect of LC n23 PUFAs to impede n26 PUFA (AA)-mediated steroidogenesis ( Figure 5 ).
DISCUSSION
This study showed for the first time to our knowledge that a greater plasma n26 concentration and n26:n23 ratio are associated with greater circulating androgen concentrations in women with PCOS. Cross-sectional data also suggested that a greater plasma LC n23 PUFA status was associated with a less atherogenic lipid profile. LC n23 PUFA supplementation reduced plasma bioavailable testosterone concentrations, most markedly in subjects who exhibited a larger reduction in plasma n26:n23 PUFAs. Targeted mechanistic studies in bovine theca cells showed an increased secretion of androstenedione after AA treatment, which suggested that the effects of n23 PUFA supplementation in PCOS women may be indirect effects, possibly through displacement or increased competition with plasma n26 PUFAs.
The balance between n26 and n23 PUFAs is of established importance, and members of these fatty acid families compete for the sn-2 position on membrane phospholipids as well as for membrane release and subsequent metabolism to form eicosanoids, which are potent fatty acid-derived metabolites (32) . Because the affinity for the enzymes governing these processes decreases from n23 PUFAs, when EPA (20:5n23) is present in sufficient amounts, the metabolism of the n26 PUFA AA (20:4n26) is repressed (33) . It has emerged that eicosanoids derived from AA are required for induction of steroidogenic acute regulatory protein and, hence, progression through the first and rate-limiting step of the steroidogenic pathway (34, 35 ). In the current study, treatment with exogenous AA up-regulated LH-induced steroidogenesis in primary bovine theca cells, as shown by increased androstenedione release into the medium, potentially because of an increased provision of substrate for the induction of steroidogenic acute regulatory protein. Therefore, as a result of competition between various fatty acids, an increase in n23 PUFAs may decrease concentrations of n26-mediated eicosanoid formation and, thus, indirectly affect pathways involved in steroidogenesis. An example of this competition has previously been shown in the endometrium (36) . The supplementation of the diet of women for 6 mo with GLA or EPA led to a decreased synthesis of prostaglandins E2 and F2a. This decrease in 2-series prostaglandins was postulated to relate to direct competition for fatty acid incorporation into phospholipids. In support of the proposed effect of n26 PUFAs in steroidogenesis, Mai et al (37) showed an increase in the androgen precursors DHEAS and androstenedione after lipid infusion (Abbolipid 20%, safflower oil and soy oil; Abbott, WiesbadenDelkenheim, Germany) in healthy men, which was an observation independent of changes in circulating insulin concentrations. More recently, this finding was further pursued by investigators within the same group in a cohort of women with PCOS, and similar results were observed after administration of the same lipid preparation (38) , which further highlighted the role of fatty acids in androgen synthesis in vivo.
Although plasma androgen concentrations were significantly reduced after LC n23 PUFA supplementation, further analysis suggested that direct effects of LC n23 PUFA may not be responsible for the androgen-concentration reduction observed because those subjects in whom the greatest changes in plasma androgen concentrations had occurred exhibited greater decreases in plasma n26: n23 PUFA ratios. Interestingly, the change in plasma EPA, DHA, or total n23 PUFA concentrations were less strongly associated with androgen-concentration reduction. This observation was further strengthened by data obtained from an independent cross-sectional cohort of PCOS cases in whom high plasma n26 fatty acid concentrations were associated with higher circulating plasma androgen concentrations. In accordance with data obtained from the intervention study on a cross-sectional level, those women with a higher plasma n26: n23 PUFA ratio exhibited greater plasma androgen concentrations despite no significant differences in BMI or insulin resistance. In support of the concept that n26 PUFAs and not n23 PUFAs may have a more direct involvement in steroidogenesis, the treatment of primary bovine theca cells with the n26 fatty acid AA led to a significant up-regulation of LH-stimulated steroidogenesis, as shown by increased androstenedione secretion relative to control and LC n23 PUFA treatments. Overall, it appeared that n26 PUFA could have affected the steroidogenic pathway, and the balance between plasma n26 and n23 PUFA concentrations may have had an indirect functional effect. Excessive androgen synthesis secondary to mutations of enzymes in the steroidogenic pathway within ovarian theca cells of women with PCOS (39, 40) may be maximized because of a diet rich in n26 PUFA. This idea is consistent with the notion that dietary components are not at the root cause of PCOS but may represent an opportunity for modulation of the hormonal component of this common condition.
The pathology of PCOS is linked with many of the metabolic aberrations for which n23 PUFAs have been shown to exert a positive effect. These include abdominal adiposity (41) chronic low-grade inflammation (42) , and postprandial dyslipideamia (20, 21) . Regarding the metabolic effects of PUFAs in PCOS, within our cross-sectional cohort of PCOS cases, higher scores for the high plasma LC n23 PUFA factor were associated with lower triacylglycerol concentrations in cohorts without PCOS (10) (11) (12) . In contrast to this cross-sectional data, LC n23 FIGURE 5. n26 Polyunsaturated fatty acid arachidonic acid (AA) played a role in the activation of steroidogenic acute regulatory protein (StAR), which is the first and rate-limiting step of the steroidogenic pathway. A: Luteinizing hormone (LH)-stimulated steroidogenesis and StAR activation involved the classic LH, cyclic AMP, and protein kinase A (LH/CAMP/PKA) pathway in addition to LH-mediated AA release and metabolism that resulted in the production of 2-series prostaglandins (PGs) and thromboxanes (TXs) and 4-series leukotrienes (LTs) through the actions of cyclooxygenase-2 (COX-2) and 5-lipooxygenase (5-LOX), respectively. PGs, TXs, and LTs are involved in StAR induction and thus help to regulate the activity of StAR in the nucleus. An increased proportion of AA within the membrane may lead to the up-regulation of this process. Conversely, an increased proportion of n23 fatty acids within the membrane would increase the competition for space within the membrane and may reduce the amount of AA available for release and therefore available for participation in StAR induction. B: Once activated, StAR is involved in the movement of cholesterol from the outer to the inner mitochondrial membrane. This is the first and rate-limiting step of the steroidogenic pathway that leads to androstenedione and testosterone production. 17b-HSD, 17b-hydroxysteroid dehydrogenase.
PUFA supplementation did not reduce fasting or postprandial triacylglycerol concentrations in women with PCOS, although this group has previously shown that a similar dose of LC n23 PUFA reduced triacylglycerol concentrations in non-PCOS populations (43) . The all-female nature of the cohort may be a potential factor to consider. The recent FINGEN (Biochemical and physiologic responsiveness to low-dose fish-oil intakes: impact of genotype, gender and geography) and LIPGENE (Diet, genomics, and the metabolic syndrome: an integrated nutrition, agri-food, social and economic analysis) studies showed that sex appears to influence the triacylglycerol-lowering action of LC n23 PUFAs, and these effects were more pronounced in men than in women (44, 45) . Similar to the findings reported in the current study, it was recently shown that supplementation with 1.9 g EPA and DHA/d for an 8-wk period did not affect fasting triacylglycerol concentrations in young women with PCOS on a whole-group level (18) . Significant reductions in triacylglycerol concentrations were only observed in a subgroup of women who displayed greater concentrations of liver fat, which suggested that dietary supplementation with LC n23 PUFA may be more effective in PCOS women with a more severe metabolic profile. In line with this, the subgroup analysis within the current study that was conducted to explore change in triacylglycerol concentrations revealed that baseline ALT concentrations were significantly greater in subjects who exhibited the greatest change in plasma triacylglycerol concentrations.
Limitations of the current study include the metabolic profile of the intervention participants. Aside from the diagnosis of PCOS, participants in the LC n23 PUFA intervention study typified a relatively metabolically healthy population who represented a spectrum of insulin resistance and lipid metabolism. The overall treatment period for the dietary intervention study may be seen as an additional potential limitation. Nutritional interventions often produce subtle effects that transpire over time; hence, the effects showed by cross-sectional studies on the basis of habitual dietary intake patterns are often not discernable from shorter interventions. An expansion of the treatment period may have afforded a clearer view of the metabolic effects of LC n23 PUFAs in PCOS, such as was suggested by a crosssectional analysis within an independent cohort. A longer duration may help to determine the potential functional outcomes that arise secondary to the androgen-lowering effect of LC n23 PUFA supplementation, such as improvements in menstrual cyclicity and ovulation. The variation in subject BMI may also be viewed as a limitation. Lean and overweight subjects were included to capture the full range of phenotypes observed within a PCOS population. It is possible that PUFAs may interact with BMI within the context of the potential antiandrogenic effect observed in PCOS, and additional studies to explore this possibility are warranted.
In conclusion, this work substantially added to the knowledge of PUFAs in PCOS and highlighted a role for these fatty acids in the treatment of metabolic and hormonal aspects of this condition. That this relation was shown in 3 separate systems substantially strengthened this overall concept. This research also presented opportunities for future work. Further manipulation of dietary intakes of women with PCOS with respect to n26 fatty acids would be of interest to ascertain whether decreases in n26 fatty acid concentrations and a subsequent lowering of the n26: n23 ratio would result in an improved hormonal profile. The determination of the optimal ratio of these fatty acids would be of benefit in the development of food-based dietary guidelines and more tailored dietary advice for women with PCOS.
